Satsuma Pharmaceuticals Announces Presentation of Two Clinical Program Abstracts at the American Headache Society's 68th Annual Scientific Meeting

DURHAM, N.C., June 4, 2026 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing innovative treatments for people living with migraine, today announced that two abstracts highlighting findings from its clinical development program have been...